Pictet Asset Management Ltd. increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.4% during the second quarter, Holdings Channel reports. The fund owned 3,026,485 shares of the company’s stock after buying an additional 12,397 shares during the period. Pictet Asset Management Ltd.’s holdings in Teva Pharmaceutical Industries Limited were worth $84,318,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Guggenheim Capital LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 40,276 shares of the company’s stock worth $1,460,000 after buying an additional 446 shares during the last quarter. Teachers Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth about $21,946,000. Chevy Chase Trust Holdings Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 3.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 6,273 shares of the company’s stock worth $201,000 after buying an additional 207 shares during the last quarter. Manning & Napier Advisors LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 15.0% in the first quarter. Manning & Napier Advisors LLC now owns 96,678 shares of the company’s stock worth $3,101,000 after buying an additional 12,645 shares during the last quarter. Finally, Country Club Trust Company n.a. raised its position in shares of Teva Pharmaceutical Industries Limited by 5.7% in the first quarter. Country Club Trust Company n.a. now owns 164,839 shares of the company’s stock worth $5,290,000 after buying an additional 8,870 shares during the last quarter. Institutional investors and hedge funds own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 18.59 on Tuesday. The firm’s 50-day moving average is $32.05 and its 200 day moving average is $32.28. The stock has a market capitalization of $18.89 billion, a P/E ratio of 238.33 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 12-month low of $18.50 and a 12-month high of $55.45.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.25 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 1.83%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -18.95%.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Position Boosted by Pictet Asset Management Ltd.” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/teva-pharmaceutical-industries-limited-teva-position-boosted-by-pictet-asset-management-ltd.html.

A number of research analysts have issued reports on TEVA shares. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $37.48 price target on the stock in a research note on Tuesday, April 11th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Citigroup Inc. cut their price target on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Saturday, April 29th. Finally, Maxim Group set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, twenty-two have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and an average target price of $39.19.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.